Canadian drugmaker Biovail announced plans to shed its US-based sales organization and related jobs in an effort to cut costs as it readies for challenges to the patent on Wellbutrin XL. The job cuts call for the elimination of 200 positions, the firm said. Biovail plans to eliminate its US specialty sales force and related support functions.